TrialBlood advances2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
Eli Muchtar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this paperpooled itcites it